使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning. My name is Melissa. And I will be your conference facilitator today. At this time I would like to welcome everyone to the ICN third quarter 2003 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer period. Please limit yourselves to one question at a time to allow all participants an opportunity to ask questions. As a reminder, this call is being recorded. At this time for opening remarks and introductions, I would now like to turn the call over to Mr. Jeff Misakian, Vice President of Investor Relations. Please go ahead sir
早安。我叫 Melissa。今天我將擔任本次會議的主持人。此刻我想歡迎各位參加 ICN 2003 年第三季財報電話會議。為避免任何背景雜音,所有線路均已設為靜音。在講者致詞後,將進行問答時間。為讓所有與會者都有機會提問,請各位一次僅提出一個問題。提醒各位,本次電話會議將被錄音。現在進入開場致詞與介紹,我想把電話交給投資人關係副總裁 Jeff Misakian 先生。先生請開始
Jeff Misakian - VP of Investor Relations
Jeff Misakian - VP of Investor Relations
Thank you Melissa. Good morning, everyone. And Welcome to ICN's third quarter 2003 earnings call. We are very pleased to be with you this morning. Before we begin, however, I'll like to call your attention to the fact that this presentation may contain forward-looking statements that may involve risks and uncertainties including but not limited to projections of future sales, royalty income, operating income returns on invested assets, regulatory approval processes, competition from generic products, marketplace acceptance of the company's products, success of the companies a strategic repositioning initiatives and the ability of management to execute them.
謝謝你,Melissa。各位早安。歡迎參加 ICN 2003 年第三季財報電話會議。我們很高興今天早上能與各位一起。不過在開始之前,我想提醒各位,本簡報可能包含前瞻性陳述,可能涉及風險與不確定性,包括但不限於對未來銷售、權利金收入、營業利益、投資資產報酬、法規核准流程、學名藥競爭、市場對公司產品的接受度、公司策略性重新定位計畫的成功,以及管理階層執行這些計畫的能力等之預測。
Cost cutting measure, success of the company's strategic plan and ability to achieve financial targets and cost reduction goals and other risks detailed from time to time in ICN's SEC filings. These statements are based on management's current expectations and involve risks and uncertainties that involve ICN's ability to retain key employees and reduce costs, general economic factors and business and capital market conditions, general industry trends and changes in tax law requirements and government regulation. ICN wishes to cautions reader that these factors, as well as other factors described in ICN's SEC filings are among the factors that could cause actual results to differ materially from the expectations described in these forward-looking statements.
成本削減措施、公司策略計畫的成功、達成財務目標與成本降低目標的能力,以及 ICN 不時在向 SEC 申報文件中所詳述的其他風險。這些陳述係基於管理階層目前的預期,並涉及風險與不確定性,包括 ICN 留任關鍵員工與降低成本的能力、整體經濟因素與商業及資本市場狀況、產業整體趨勢,以及稅法要求與政府監管的變動。ICN 提醒讀者注意,這些因素以及 ICN 向 SEC 申報文件中所描述的其他因素,均可能導致實際結果與上述前瞻性陳述所描述的預期出現重大差異。
Joining us on the call today are Robert W O'Leary, ICN's Chairman and Chief Executive Officer. Timothy C Tyson, President and Chief Operating Officer. And Bary G Bailey, Executive Vice President and Chief Financial Officer. Dr. Kim Lamon, President R&D and Chief Scientific Officer. Wes Wheeler, President North American Global Marketing and Business Development. Willi Wu Controller and Bill Robert, Treasurer are also here to answer questions during the question and answer session. Now I would like to turn the call over to Mr. O'Leary. Robert?
今天與會者包括 ICN 董事長兼執行長 Robert W O'Leary。總裁兼營運長 Timothy C Tyson。執行副總裁兼財務長 Bary G Bailey。研發總裁兼首席科學長 Kim Lamon 博士。北美全球行銷與業務發展總裁 Wes Wheeler。會計主管 Willi Wu 與財務主管 Bill Robert 也在場,將於問答時段回答問題。現在我想把電話交給 O'Leary 先生。Robert?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Thank you, Jeff. Good morning, everyone. Thank you for joining us. We announced results for the third quarter this morning that reflect the execution on a number of fronts. While our results include a decline in royalty revenues and the financial impact from some of our strategic initiatives, our core business, the business we can influence continued to make remarkable progress in this quarter. Total revenues from continuing operations decreased 2% in the current quarter compared to a year ago. Primarily due to the royalty revenue decline. However, product sales from the specialty pharma business increased 21% in the same period.
謝謝你,Jeff。各位早安。感謝各位參與。我們今天早上公布了第三季的業績,反映我們在多個面向的執行成果。雖然我們的結果包含權利金收入下滑以及部分策略性措施帶來的財務影響,但我們的核心業務——也就是我們能夠影響的業務——在本季仍持續取得顯著進展。本季持續營運的總營收較去年同期下降 2%。主要原因是權利金收入下滑。然而,專科製藥業務的產品銷售在同一期間成長 21%。
Tim Tyson will provide you with more information about our product sales in a few minutes. I am particularly pleased with the strong management team we have built here at ICN that continues to deliver on our focused strategy while maintaining an adherence to strict control over operating expenses. This focus continued to pay off in the third quarter. With an increase in product sales and expansion of our gross margin and continued improvement in our expense ratios. As a result, operating income in the specialty pharma business from which we exclude our R&D division increased substantially to a profit of 21.9 million in the third quarter from a loss a year ago.
Tim Tyson 將在幾分鐘後提供更多關於我們產品銷售的資訊。我特別高興的是,我們在 ICN 建立了一支強大的管理團隊,持續在嚴格控管營運費用的同時,落實我們聚焦的策略。這樣的聚焦在第三季持續帶來成效。產品銷售增加、毛利率擴大,且費用比率持續改善。因此,專科製藥業務(我們排除研發部門)之營業利益大幅提升,第三季由去年同期的虧損轉為獲利 2,190 萬。
Royalty revenue from the sales of ribovirin declined 43% in the third quarter compared to last year. The decline in royalties is consistent with the information disclosed in Shering plows third quarter announcement and the market place dynamics. While we continue to pursue legal and regulatory relief we are operating under the assumption that generic manufacturers of ribovirin will enter the United States before the end of the year which we expect to further impact ribovirin sales and royalties we receive.
來自 ribovirin 銷售的權利金收入在第三季較去年下降 43%。權利金下滑與 Shering Plow 第三季公告所揭露的資訊及市場動態一致。雖然我們仍持續尋求法律與監管上的救濟,但我們的營運假設是:在年底前 ribovirin 的學名藥製造商將進入美國市場,我們預期這將進一步影響 ribovirin 的銷售以及我們所收到的權利金。
ICN successful reapplied the minority interest in Riba pharm this quarter and we merged Riba pharm operations into our own. This was the culmination of a long process in which we concentrated on the best outcome for our shareholders and frankly never took our eye off the ball. Merging Riba Pharm, which is now our R&D division into ICN was clearly the right thing to do and our shareholders have already begun to realize the benefits. The acquisition did trigger a one-time write-off of $117.6 million of in process research and development expenses which resulted in a net loss in the third quarter of 82.4 million and a loss from continuing operations of 98.5 million.
本季 ICN 成功重新取得 Riba Pharm 的少數股權,並將 Riba Pharm 的營運併入我們自身。這是長期流程的最終成果,我們專注於為股東爭取最佳結果,坦白說,我們從未分心。將 Riba Pharm(現為我們的研發部門)併入 ICN 顯然是正確之舉,我們的股東也已開始享受到其效益。此次收購觸發一次性認列 1.176 億美元的在研研發費用減損,導致第三季淨損 8,240 萬美元,且持續營運虧損 9,850 萬美元。
However, when you exclude the one-time write-off from in process R&D income from continuing operations was a positive $19.1 million or 23 cents per diluted share. This is a penny ahead of the first call consensus estimate in spite of the substantial decline in royalty revenue and speaks once again not only to the strength but to the potential of our core business. We have now almost nearly wrapped up all of you are a divestiture activity which we report to you in our operations. Our divestiture team was active again this quarter continuing to execute ahead of schedule on the safely our non-core assets.
然而,若排除一次性的在研研發費用減損,持續營運的收益為正的 1,910 萬美元,或稀釋後每股 0.23 美元。儘管權利金收入大幅下滑,這仍比市場一致預估高出 1 美分,再次顯示我們核心業務不僅具備實力,也具備潛力。我們現在幾乎已完成所有的資產剝離活動,並在營運中向各位報告。本季我們的剝離團隊再次積極行動,持續提前進度執行出售我們的非核心資產。
We sold the cemetery business and recorded a begin on the sale as well as a $58 million increase in our cash. We now have only our much smaller API business in the Czech republic and Hungary left to divest and we expect to complete that soon. Bary Bailey will provide you with more details on our financial performance for the third quarter in a few minutes. Importantly, we also announced this morning that the company has decided to initiate phase three studies on verity, our lead anti-viral compound that we intend to develop in oral form for the treatment of hepatitis C.
我們出售了墓園業務,並就該出售認列收益,同時現金增加 5,800 萬美元。目前僅剩規模更小的 API 業務(位於捷克共和國與匈牙利)待剝離,我們預期很快完成。Bary Bailey 將在幾分鐘後提供第三季財務表現的更多細節。重要的是,我們今天早上也宣布,公司已決定啟動 verity 的第三期研究;verity 是我們領先的抗病毒化合物,我們計畫以口服劑型開發,用於治療 C 型肝炎。
Our decision follows a meeting with the FDA in early September in which the company presented interim analysis of 12 weeks of clinical data in a phase 2 trial. We are pleased with this development and that we are proceeding into phase three. We have scheduled an investigators meeting for later this month and expect to enroll our first patient in the phase three studies by the end of the year. Hopefully, you have seen our press release announcing this development with verity. We will be somewhat limited in what we can add to that release in this mornings call so we refer you to it.
此決定是在 9 月初與 FDA 會議之後作出,會中公司提出第二期試驗 12 週臨床資料的期中分析。我們對此進展感到欣慰,並將推進至第三期。我們已安排本月稍晚舉行研究者會議,並預期在年底前於第三期研究中納入第一位受試者。希望各位已看到我們發布的新聞稿,宣布 verity 的此項進展。在今天早上的電話會議中,我們能補充的內容會有所限制,因此請各位參閱該新聞稿。
And in fact, we are very proud of our third quarter results and we are going to focus our attention on this call on those results. With that, I would like to turn the call over to Tim Tyson, our President for a review of our regional and on product performance.
事實上,我們對第三季的業績成果感到非常自豪,而本次電話會議也將把重點放在這些結果上。接下來,我想把電話交給我們的總裁 Tim Tyson,請他回顧我們各區域以及產品的表現。
Timothy Tyson - President and COO
Timothy Tyson - President and COO
Thank you, Robert. Good morning, everyone. We are very pleased with the steady progress made this quarter in a our specialty pharmaceutical business. As you can see in the results published this morning, we saw both top and bottom line improvements in nearly all regions. North America which represents our most important opportunity stood out with the strongest performance in the quarter compared to last year. North American sales in the third quarter were $29.4 million. An increase of 75% over a year ago. Operating income for North American was $12.9 million in the third quarter versus a loss in the same quarter last year.
謝謝你,Robert。各位早安。我們對本季在我們的專科製藥業務所取得的穩健進展感到非常滿意。如同各位在今天早上公布的業績中所見,我們在幾乎所有地區的營收與獲利表現皆有所改善。北美是我們最重要的機會所在,與去年相比,本季表現最為突出。第三季北美銷售額為2,940萬美元。較一年前成長75%。北美第三季營業利益為1,290萬美元,而去年同期則為虧損。
We saw improvement in several products in North American, particularly in our core dermatological business. Active X sales increased in the third quarter due to the restructuring out of a US sales force and strong promotional effort and remains the leader for the treatment of acetonic care toes with a 52% share of the US market. We recently re-launched an effective further treatment for severe psoriasis. Sales of actor Lin(ph) were up significantly in the third quarter and are expected to continue to increase as we approach the peak winter season.
我們看到北美多項產品有所改善,尤其是在我們的核心皮膚科業務。由於美國銷售團隊的重整以及強而有力的推廣活動,Active X第三季銷售增加,並以52%的美國市場占有率,持續領先用於治療痤瘡的產品。我們近期重新推出一項針對重度乾癬的有效進一步治療方案。actor Lin(ph)第三季銷售大幅成長,且預期隨著冬季旺季接近將持續增加。
Our Hydrocilin known flu-like Quinn is holding total market share just slightly introduction of new products. Annually our products for fine line and wrinkles continues to grow and is now being advertised to consumers. We have also seen strong growth in Sesamet (ph) an anti-hematic in Canada. Mestinon, our leading global product and product for the treatment for myasthenia gravis continued to be a strong contributor in North American despite of genuine competition. Our defense strategy has helped us retain business at more than 50% of total prescription which is significantly above what typical erosion models would predict. It is important you note that last year's third quarter was impacted by our reduction measures which we completed in April of this year.
我們的Hydrocilin(亦稱flu-like Quinn)在新產品推出的情況下,仍僅略微影響其整體市場占有率。我們用於細紋與皺紋的產品每年持續成長,且目前已開始對消費者投放廣告。我們也看到Sesamet (ph)在加拿大作為抗嘔吐藥的強勁成長。Mestinon作為我們全球領先產品、用於治療重症肌無力,儘管面臨學名藥競爭,在北美仍持續做出強勁貢獻。我們的防禦策略協助我們將業務維持在總處方量的50%以上,顯著高於典型侵蝕模型的預測。請注意,去年第三季受到我們削減措施的影響,而該措施已於今年四月完成。
Sales in Europe in the third quarter totaled $54.5 million which represents a 23% increase over the same period last year. European sales were aid by the strength of foreign currencies which added $4.8 million in the quarter. In addition, we saw sales growth in Poland and other central European countries. Major contributors were Mestinon and Kelsatonin (ph). Operating income in Europe improved significantly totaling $8.4 million in the third quarter compared to a near break-even results a year ago due to good financial management.
歐洲第三季銷售總額為5,450萬美元,較去年同期成長23%。歐洲銷售受惠於外幣走強,本季增加了480萬美元。此外,我們在波蘭及其他中歐國家也看到銷售成長。主要貢獻產品為Mestinon與Kelsatonin (ph)。由於良好的財務管理,歐洲營業利益顯著改善,第三季達840萬美元,而去年同期接近損益兩平。
Europe continues to deliver impressive results in spite of tremendous challenges with German health care reform, reference pricing in Spain and Italian price controls. We have further strengthened this important region through leadership changes that we believe will drive further growth.
儘管面臨德國醫療改革、西班牙參考定價以及義大利價格管制等重大挑戰,歐洲仍持續交出亮眼成果。我們透過領導層調整進一步強化這個重要地區,我們相信這將帶動進一步成長。
This quarter, we announced the appointment of Charles W Bramlage as President of our European operations. Mr. Bramlage brings more than 20 years of pharmaceutical experience to ICN including significant sales and marketing expertise. It's a privilege to have someone of Mr. Bramlage his experience and capabilities join ICN. In connection with Mr. Bramlage appointment, we reorganized and consolidated our European operations.
本季我們宣布任命Charles W Bramlage為我們歐洲營運總裁。Bramlage先生為ICN帶來超過20年的製藥產業經驗,其中包含豐富的銷售與行銷專長。能有像Bramlage先生這樣具備經驗與能力的人加入ICN,是我們的榮幸。配合Bramlage先生的任命,我們已對歐洲營運進行重整與整併。
Latin America sales increased 9% in the third quarter to $34.7 million. Operating income in Latin America improved as well. Increasing 6 percent in the quarter to $11.8 million. These improvements primarily reflect unit and price increases in the quarter offset by a negative currency variance. We continued to see an impact from generic substitution in the region.
拉丁美洲第三季銷售成長9%,達3,470萬美元。拉丁美洲的營業利益也有所改善。本季成長6%,達1,180萬美元。這些改善主要反映本季銷量與價格上升,但部分被不利的匯率差異所抵銷。我們仍持續看到該地區學名藥替代所帶來的影響。
The steps we have taken to realign and increase our sales force as well as to improve our targeting strategies are beginning to pay off. Our AAA region experienced a decline in sales of 17% in the quarter to $12.6 million.
我們為重新調整並擴充銷售團隊,以及改善目標客群策略所採取的措施,正開始見到成效。我們的AAA地區本季銷售下滑17%,至1,260萬美元。
However, operating income improved significantly with a one point million-dollar profit in the third quarter compared to a loss reported in the same period last year. Sales in the current quarter were lower primarily because of a reduction in sales of Restalase (ph), a key product in the region. We have submitted an application for an import license for Restalase. We have further strengthened our management team with the appointment of David Kuo(ph) as EVP of the AAA region.
然而,營業利益顯著改善,第三季獲利110萬美元,而去年同期則為虧損。本季銷售較低主要是因為該地區關鍵產品Restalase (ph)的銷售下滑。我們已提交Restalase的進口許可申請。我們也任命David Kuo(ph)為AAA地區執行副總裁(EVP),進一步強化管理團隊。
Mr. Kuo brings over 30 years of pharmaceutical experience with a strong background in general management, marketing business development. Mr. Kuo's experience and contacts in the critical Asian region will be particularly important as the company further develops its hepatitis franchise in this area.
Kuo先生擁有超過30年的製藥產業經驗,在一般管理、行銷與業務開發方面具備深厚背景。隨著公司在此關鍵亞洲地區進一步發展其肝炎產品線,Kuo先生在當地的經驗與人脈將格外重要。
Our research and development division has been very successful. With the past distractions of the old RIBA pharm structure removed. Our teams are now fully concentrated on science and discovery. All of our projects are at or ahead of internal schedules.
我們的研發部門非常成功。隨著舊有RIBA pharm架構所造成的干擾已被排除。我們的團隊如今能全力專注於科學與探索。我們所有專案皆達到或超前內部時程。
Our lead product in the pipeline at the moment is Vera Deen (ph). As Robert indicated, this will be transitioning into phase three by the end of the year. Most of you are also aware of Hepaveer B (ph); our compound under development for the treatment of Hepatitis B. Hepaveer B is a pro drug of PMEA and is currently in late phase one clinical evaluation.
目前我們研發管線中的主力產品是Vera Deen (ph)。如Robert所指出,該產品將在年底前進入第三期臨床試驗。各位多數也知道Hepaveer B (ph);這是我們正在開發、用於治療B型肝炎的化合物。Hepaveer B是PMEA的前驅藥(prodrug),目前正處於第一期後段的臨床評估。
We have expanded the program to Asia where we have filed an IMD in Taiwan and conducted an investigators meeting for a phase one study expected to begin in the fourth quarter. We hope to move Hepaveer B to phase two sometime in the first half of next year. We're in the process of designing the protocol for the phase two study, which we intend to conduct in Asia.
我們已將該計畫擴展至亞洲,並已在台灣提交IMD,且召開了研究者會議,為預計於第四季開始的第一期研究做準備。我們希望在明年上半年某個時間將Hepaveer B推進至第二期。我們正在設計第二期研究的試驗方案,並計畫在亞洲進行。
In addition we are moving forward aggressively with our growth plans in identifying key acquisition targets. We expect to announce our first acquisition by early next year. In the meantime, we're busy working on more than 20 life cycle expansion projects internally.
此外,我們也正積極推動成長計畫,辨識關鍵併購標的。我們預期在明年初宣布第一起收購案。同時,我們也忙於內部超過20項產品生命週期延伸專案。
We also announced our first ever direct to consumer advertising campaign for Kin erase. Which is designed to generate 35-million consumer impression. Kin erase has broad consumer appeal and we are hopeful the DTC campaign will significantly increase sales of this core brand. But it's still early in this campaign.
我們也宣布首次針對Kin erase的直接面向消費者(DTC)廣告活動。該活動旨在創造3,500萬次的消費者曝光。Kin erase具有廣泛的消費者吸引力,我們希望DTC活動能顯著提升這個核心品牌的銷售。不過,這項活動仍在初期階段。
Finally, we have recently announced our global manufacturing and supply initiative and began implementation of our manufacturing rationalization efforts. As a result of this initiative, we will establish a global network of five manufacturing facilities and sell eight facilities from continuing operations.
最後,我們近期宣布全球製造與供應倡議,並開始推動製造合理化的執行工作。透過此倡議,我們將建立由五座製造設施組成的全球網絡,並出售持續營運中的八座設施。
This comprehensive strategy will enable us to achieve our commitment to restructure our operations, achieve cumulative cost savings of between 150 and $200 million dollars over five years and significantly reduce our cost of goods sold to 20 to 25%. We recently launched a corporate-wide operational excellence initiative, which has at its core the lean six-sigma process. We expect this initiative to deliver significant financial benefits in the coming years. I'll now turn the call over to Bary Bailey for a discussion of our financial performance. Bary?
這項全面性策略將使我們得以履行重整營運的承諾,在五年內達成累計1.5億至2億美元的成本節省,並將銷貨成本占比大幅降低至20%至25%。我們近期啟動全公司營運卓越倡議,其核心為精實六標準差(Lean Six Sigma)流程。我們預期此倡議在未來幾年將帶來顯著的財務效益。接下來我把電話交給Bary Bailey,請他說明我們的財務表現。Bary?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Thank you, Tim. And again, thank you everyone for joining us today. Overall, our financial performance in the third quarter can be characterized as steady and consistent progress toward our goals. As you have already heard, our top line performance from the specialty pharma business was strong and we continue to hold the line on expenses.
謝謝你,Tim。也再次感謝各位今天與會。整體而言,我們第三季的財務表現可概括為:朝向目標穩健且一致地推進。如各位已聽到的,我們專科製藥業務的營收表現強勁,同時我們也持續嚴控費用。
Our gross margin expanded in the third quarter to 68% from 63% in the same period last year. The increase was primarily due to favorable changes in both geographic and product sales mix. With more sales coming from our higher margin products overall, particularly in North America this year and efficiencies in our manufacturing operations.
我們第三季毛利率由去年同期的63%擴大至68%。此一增加主要來自地區與產品銷售組合的有利變化。整體而言,更多銷售來自毛利率較高的產品,尤其是今年北美地區,同時也受惠於我們製造營運效率的提升。
Selling expenses in the third quarter were basically flat compared to the same period last year in spite of a 21% increase in product sales. General and administrative expenses were down 17% in the third quarter reflecting our ongoing efforts to keep costs under control.
第三季的銷售費用與去年同期基本持平,儘管產品銷售成長了21%。第三季的一般及行政費用下降了17%,反映我們持續致力於將成本控制在可控範圍內。
We will continue to appropriately manage costs in this area. You should also note that the third quarter included one-time expenses of 4.5 million for legal, banking and consulting fees incurred by RIBA pharm in connection with the acquisition.
我們將持續在此領域適當地管理成本。您也應注意,第三季包含一次性費用450萬,用於RIBA pharm因收購案所產生的法律、銀行及顧問費用。
Selling expense as a percent of sales dropped to 31% in the 2003 third quarter from 37% in the same period last year as a result of cost control and good investment choices. Overall, our lower -- we lowered our SG&A to 50% of sales in the current quarter from 65% a year ago. Significant improvement in key metrics for this company. As Tim mentioned our global manufacturing and supply initiatives will result in the sale of eight facilities from our continuing operation.
由於成本控制與良好的投資選擇,2003年第三季銷售費用占銷售額的比例由去年同期的37%降至31%。整體而言,我們將本季的SG&A降至銷售額的50%,而一年前為65%。公司關鍵指標顯著改善。如Tim所提,我們的全球製造與供應計畫將使我們從持續營運中出售八處設施。
We previously had indicated that a one-time charge related to the sale of these facilities might occur this year. We have performed impairment tests on each of the facilities to be sold in accordance with applicable accounting rules and determined that none of the facilities actually met the technical or impairment test criteria for asset write-downs. Thus no one-time charges are expected for the sales at this time.
我們先前曾表示,與出售這些設施相關的一次性費用可能會在今年發生。我們已依據適用的會計準則,對每一處擬出售設施進行減損測試,並判定實際上沒有任何設施符合資產減記的技術性或減損測試標準。因此,目前預期這些出售不會產生一次性費用。
However, we did determine that it was appropriate to accelerate depreciation on these plants over their estimated remaining life of approximately two years. Impacts of the incremental depreciation expense, which is included in cost of goods sold, will be approximately $1.6 million in the fourth quarter and $6.4 million per year for the next two years.
然而,我們確定適宜在約兩年的估計剩餘使用年限內,加速對這些廠房提列折舊。新增折舊費用(已包含於銷貨成本中)的影響,第四季約為160萬美元,未來兩年每年約為640萬美元。
This will have the impact of reducing our gross margins for the periods covered. As previously announced, we completed the RIBA pharm acquisition in the third quarter for $6.25 cash per share. And merged Riba pharm's operations into those of ICN. Minority interest in Ribapharm has been recorded through the date of the merger. The total purchase price in the transaction was $207.4 million, which includes costs and fees incurred by ICN associated with the buy-in.
這將使涵蓋期間的毛利率下降。如先前公告,我們於第三季以每股6.25美元現金完成對RIBA pharm的收購。並將Riba pharm的營運併入ICN。Ribapharm的少數股權已記錄至合併日為止。本交易的總購買價格為2.074億美元,其中包含ICN就買入交易所產生的相關成本與費用。
Minority interest on the balance sheet of $33.9 million, was eliminated in the transaction and the remainder of the purchase price was allocated between in process R&D of $117.6 million. Ribavirin royalty intangibles of $67.4 million and good will of $12.8 million.
資產負債表上3,390萬美元的少數股權在交易中已予以沖銷,其餘購買價格則分配為:在研研發(in process R&D)1.176億美元、Ribavirin權利金無形資產6,740萬美元,以及商譽1,280萬美元。
The in process R&D was written off in the third quarter and is reported separately in the income statement. The intangible assets associated with the Ribavirin royalties is being amortized over the next five years on an accelerated basis based on a projected royalty stream. The impact of this amortization in the third quarter was $1.9 million nd is expected to be $5 million in the fourth quarter and 17.5 million in 2004.
在研研發已於第三季一次性沖銷,並在損益表中單獨列示。與Ribavirin權利金相關的無形資產,將依預估權利金收入流,以加速方式於未來五年攤銷。此攤銷對第三季的影響為190萬美元,預期第四季為500萬美元,2004年為1,750萬美元。
Our provision for income taxes from continuing operations of 38% in the quarter, which was in line with our expectations. We expect to remain at this rate for the remainder of 2003. We continued to move aggressively in shedding non-core assets, which we classify as discontinued operations. In the third quarter, we completed the sale of our symmetry unit which resulted in an after tax gain of $23 million. Our API business in the Czech republic and Hungary is the only business that remains to be sold.
本季持續營運的所得稅費用率為38%,符合我們的預期。我們預期2003年剩餘期間將維持此稅率。我們持續積極處分非核心資產,並將其分類為停業部門。第三季我們完成出售Symmetry事業單位,稅後處分利益為2,300萬美元。位於捷克與匈牙利的API業務是唯一尚待出售的業務。
During the third quarter we recorded an additional impairment charge on the API business of $6.2 million reflect the fair value of the net assets to be sold. Obviously this charge was recorded in discontinued operations. As a result, the remaining net assets of discontinuing operations totaled $8 million at September 30.
第三季我們就API業務額外認列620萬美元的減損費用,以反映待出售淨資產的公允價值。顯然,該費用已列入停業部門。因此,截至9月30日,停業部門剩餘淨資產合計為800萬美元。
Cash at September 30th totaled $301 million, which is a significant increase over our cash balance at the beginning of the year but a decline from the balance at June 30th. The acquisition of RIBA pharm in the third quarter reduced cash by approximately $200 million. This was partially offset by the 58 million in cash received in the symmetry sale as well as net sale of cash from operations.
截至9月30日,現金總額為3.01億美元,較年初現金餘額大幅增加,但較6月30日的餘額下降。第三季收購RIBA pharm使現金約減少2億美元。部分由出售Symmetry所收到的5,800萬美元現金,以及營運所產生的淨現金流入所抵銷。
We believe that our cash on hand is efficient to fund our operations for the foreseeable future. We remain comfortable with our five-year targets and metrics for 2004. As Robert mentioned earlier, we expect U.S. ribovirin royalties to be subject to considerable uncertainty for the remainder of this year and into 2004. But we continue to be comfortable with the stability of royalties for non U.S. markets.
我們相信手上現金足以支應可預見未來的營運資金需求。我們對2004年的五年期目標與指標仍感到安心。如Robert先前提到,我們預期美國Ribovirin權利金在今年剩餘期間及進入2004年仍將面臨相當大的不確定性。但我們對非美國市場權利金的穩定性仍然有信心。
We continue to feel quite comfortable with the pieces of the business that we can control and we'll continue to update the street on the metrics and market factors that investors need to evaluate our business potential. And with that, I will turn the call back over to Robert. Robert?
對於我們能掌控的業務組成部分,我們仍然相當有信心,並將持續向市場更新投資人評估我們業務潛力所需的指標與市場因素。接下來,我把電話交回給Robert。Robert?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Thank you, Bary. All this year, you've heard us talk about the transform imagination of ICN from an old world intrapreneurially run enterprise to a truly modern integrated operating company. You have heard us talk about what is arguably one of the strongest management teams under development in the industry. This team has the experience and knows how to deliver results.
謝謝你,Bary。今年以來,你們聽到我們談到ICN的轉型想像:從一個以企業家式內部經營的舊世界企業,轉變為真正現代化、整合式的營運公司。你們也聽到我們談到,這可能是業界正在打造中最強的管理團隊之一。這個團隊具備經驗,也知道如何交付成果。
You heard us layout our strategic plans and set targets to drive performance at the Bear Stearns conference in New York. The results of the third quarter are just a foreshadowing of what we believe we can do. And what we think we can achieve. As we conclude our restructuring phase, we will focus greater attention on the transformation and growth phases we discussed in our strategic plan.
你們也聽到我們在紐約的Bear Stearns會議上闡述策略計畫並設定推動績效的目標。第三季的結果只是我們相信自己能做到之事的前兆。也是我們認為能夠達成之事的預告。隨著我們結束重整階段,我們將把更多注意力放在策略計畫中所談到的轉型與成長階段。
While we expect to deliver even stronger results as we move through these phases in the future, it's appropriate this morning to remind you that we expect the remainder of 2003 and 2004 to be foundation building periods as we work through the early stages of our transformation effort.
雖然我們預期在未來推進這些階段時能交出更強勁的成果,但今天早上也適合提醒各位:我們預期2003年剩餘期間及2004年將是打基礎的時期,因為我們仍在推動轉型工作的早期階段。
The largest benefits we expect to achieve are scheduled for 2005 and beyond as we move beyond transformation and further into the growth phase. We expect to achieve the targets that we have presented, but also want you to know that this is a management team that is focused on the long-term value and not just short-term gain.
我們預期可取得的最大效益將安排在2005年及之後,屆時我們將走出轉型、進一步進入成長階段。我們預期能達成已提出的目標,但也希望你們了解,這個管理團隊專注於長期價值,而不僅是短期收益。
We believe in steady progress, but we will never manage this business just to hit a quarterly earnings estimate. This, of course, should come as no surprise to those of you who know this team, but it bears repeating as we move into the next phase of our strategic plan. I want to thank you now for your time and we would like to now open the line to questions. Operator may we have the first question, please.
我們相信穩健的進展,但我們絕不會只為了達到單季盈餘預估而經營這項業務。對於了解這個團隊的各位而言,這當然不令人意外,但在我們進入策略計畫的下一階段時,仍值得再次強調。現在我要感謝各位撥冗參與,我們接下來開放提問。接線員,請問可以開始第一個問題嗎?
Operator
Operator
At this time if you would like it ask a question; please press "*1" on the telephone keypad. Again, please limit yourselves to one question at a time, as we were like to give everyone a chance to ask a question. If you have a follow-up question you may re-enter the queue. We'll pause for just a moment to compile the question and answer session. Your first question comes from Michael Tong with Wachovia Securities.
此時若您想提問,請在電話鍵盤按「*1」。再次提醒,請各位一次只提一個問題,因為我們希望讓每個人都有機會提問。若您有追問問題,可重新排入隊列。我們將稍作停頓以彙整問答環節。第一個問題來自Wachovia Securities的Michael Tong。
Michael Tong - Analyst
Michael Tong - Analyst
Hi, good morning. Congratulations on the quarter and thanks for taking the question. Just a background question on the phase two with respect to Viramidine was that done in conjunction with phenylated Interferon or Interferon or by itself? And as a follow-up to that, how much do you think a phase three of this rise would run?
嗨,早安。恭喜本季表現,也謝謝讓我提問。我有個背景問題:關於Viramidine的第二期試驗,是與聚乙二醇化干擾素(pegylated Interferon)或干擾素合併進行,還是單獨進行?另外追問一下,你們認為這項藥物的第三期試驗大概會需要多少費用?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Michael, thank you very much. I just want to precede our efforts to respond here with a really strong reminder; all of you, or most of you who have been involved with this company know we have some history here. And rarely have certain orders and directions that constrain us in our ability to talk about FDA matters. We were going to continually refer you back as much as possible to the press release to the extent that we can elaborate beyond that, it will be very limited, but we will try when it's appropriate. Tim, can you help them with the questions?
Michael,非常感謝你。我想在我們開始回應之前先強烈提醒一下;你們各位,或是大多數曾參與這家公司的人都知道,我們在這方面有一些歷史。而且我們很少會收到某些命令與指示,限制我們談論 FDA 相關事項的能力。我們會在可行範圍內盡可能請各位回到新聞稿;若要在其之外再做延伸說明,能補充的會非常有限,但在適當時我們會嘗試。Tim,你能協助他們回答問題嗎?
Timothy Tyson - President and COO
Timothy Tyson - President and COO
Michael, as you saw in the release, what we saw at week 12 was a clinical significant reduction in viral load. And when you compare that to ribovirin from a safety point of view, hemoglobin levels were about half that of what was seen with ribovirin. Now additional data including the drugs used and more detailed results, we expect to present in a scientific forum yet to be decided on.
Michael,如同你在新聞稿中看到的,我們在第 12 週看到病毒量在臨床上具有顯著意義的下降。而從安全性的角度與 ribovirin 相比,血紅素水準大約只有 ribovirin 所見的一半。至於更多資料,包括使用的藥物與更詳細的結果,我們預期會在尚待決定的科學論壇上發表。
Michael Tong - Analyst
Michael Tong - Analyst
Right. But, can you talk about whether there was Interferon in phase two or not?
好的。但是,你能談談第二期是否有使用干擾素嗎?
Timothy Tyson - President and COO
Timothy Tyson - President and COO
Oh, definitely. There was a phenylated Interferon in combination with ribovirin and Vir amidine.
喔,當然。有使用聚乙二醇化干擾素,並與 ribovirin 及 Vir amidine 併用。
Michael Tong - Analyst
Michael Tong - Analyst
Great. That's what I was getting at. And the potential cost of a phase three trial of this size?
很好。這正是我想問的。那麼,這種規模的第三期試驗可能的成本是多少?
Timothy Tyson - President and COO
Timothy Tyson - President and COO
I'm sorry; I missed the first part of that question?
不好意思;我漏聽了問題的前半段?
Michael Tong - Analyst
Michael Tong - Analyst
Just, how much a trial of this size would run from a phase three perspective?
就是,從第三期的角度來看,這種規模的試驗大概要花多少錢?
Timothy Tyson - President and COO
Timothy Tyson - President and COO
Well, as you know, clinical trials in phase three can be very expensive. What I have said before I haven't pegged a number but they can certainly be in the tens of millions of dollars.
嗯,如你所知,第三期臨床試驗可能非常昂貴。我之前說過我沒有訂出一個數字,但它們確實可能是數千萬美元的等級。
Michael Tong - Analyst
Michael Tong - Analyst
OK. Great. Thanks, I'll get back in queue.
好的。很好。謝謝,我回到隊列裡。
Timothy Tyson - President and COO
Timothy Tyson - President and COO
Thank you.
謝謝你。
Operator
Operator
Your next question comes from a Robert Uhl with Wells Fargo.
下一個問題來自 Wells Fargo 的 Robert Uhl。
Robert Uhl - Analyst
Robert Uhl - Analyst
Thank you. Just another one on the Vir amidine trials. Will this therapeutic regimen be pretty much like the current regimen of 48 weeks of treatment and six months of follow-up in the phase Three? Also, is this a worldwide multi national hundreds of centers type of thing?
謝謝。再問一個關於 Vir amidine 試驗的問題。在第三期中,這個治療方案是否大致會像目前的療程:治療 48 週並追蹤 6 個月?另外,這會是全球性的多國、數百個中心那種試驗嗎?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Robert, yes, it is a global trial or they will be global trials. And the trial design, as you pointed out, is pretty standard now for hepatitis C. You treat patients for 48 weeks, take them off therapy for 24, then you measure their viral tooiters (ph). That's the patient participation. There's a set up phase, enrollment phase and a phase at the end to analyze the data.
Robert,是的,這是一項全球試驗,或將會是全球試驗。而試驗設計如你所指出的,現在對 C 型肝炎而言相當標準:治療病人 48 週,停藥 24 週,然後測量他們的病毒滴度(ph)。這就是病人的參與部分。另外還有建置期、收案期,以及最後用來分析資料的階段。
Operator
Operator
Your next question comes from a Andrew Sidoti from William Smith and Company.
下一個問題來自 William Smith and Company 的 Andrew Sidoti。
Andrew Sidoti - Analyst
Andrew Sidoti - Analyst
Could you talk about how we should think about growth rates out of ribovirin outside of the U.S.? Is it growing overseas?
你能談談我們應該如何看待美國以外 ribovirin 的成長率嗎?海外有在成長嗎?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Surely. The current quarter has been impacted significantly as you know from the sharing release and our current results reflect about 60% of non-U.S. --of the royalties about 60% are non-U.S. That should give you an indication they're stable or growing in Europe.
當然。如你所知,本季受到分潤(sharing)公告的顯著影響,而我們目前的結果顯示約 60% 的非美國——也就是權利金約 60% 來自非美國。這應該能讓你看出它們在歐洲是穩定或成長的。
Andrew Sidoti - Analyst
Andrew Sidoti - Analyst
And in other parts of the world?
那在世界其他地區呢?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Stable or growing in other parts of the world. So 60 percent of our current performance is for rest of world not just European, it's for all of the rest of the world.
在世界其他地區也是穩定或成長。所以我們目前表現的 60% 來自世界其他地區,不只是歐洲,而是所有其他地區。
Andrew Sidoti - Analyst
Andrew Sidoti - Analyst
OK. Thank you.
好的。謝謝。
Operator
Operator
Your next question comes from a Alan Seymour (ph) with Columbia Management.
下一個問題來自 Columbia Management 的 Alan Seymour(ph)。
Alan Seymour - Analyst
Alan Seymour - Analyst
Hi. My question has do with, you mentioned I think the remaining assets of discontinue -- are 8 million. The question has to do with the operations in Yugoslavia, it seems to me those are written down a long time ago. What's the status of those? I presume anything you get out of there is cash?
嗨。我的問題是關於,你提到我想已停止(discontinue)的剩餘資產是 800 萬。問題與南斯拉夫的營運有關;在我看來那些很久以前就已經減記了。那些目前的狀態如何?我猜從那裡拿回來的任何東西都會是現金?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
The operation in Yugoslavia was completely written off prior to the change in management team. There is a case currently being arbitrated in Paris relative to the G&A Len ka assets. We continue to pursue that, but in fact there is nothing on our books for this nor do we project anything in the Mariucci, we're just going to see in a through to conclusion. We don't envision that market being a significant part of our future.
南斯拉夫的營運在管理團隊更替之前就已完全沖銷。目前在巴黎有一件與 G&A Len ka 資產相關的案件正在仲裁中。我們會持續追訴,但事實上我們的帳上對此沒有任何列帳,我們在 Mariucci 也不做任何預估;我們只是會把它一路看到結案。我們不認為那個市場會成為我們未來的重要部分。
Alan Seymour - Analyst
Alan Seymour - Analyst
Thanks.
謝謝。
Operator
Operator
Your next question comes from Matt Tiplus with Quaker Capital Management.
下一個問題來自 Quaker Capital Management 的 Matt Tiplus。
Matt Tiplus - Analyst
Matt Tiplus - Analyst
With respect to your specialty pharma operations, obviously very impressive on a year over year end sequential basis. Is this a maintainable sort of base from which to grow the business going forward? I gather, I guess it will be a higher depreciation charge. But that aside, I mean is this level fl profitability sustainable and can it be grown from here? Is there anything seasonal, I guess, is my question or catch up going on?
就你們的專科藥品(specialty pharma)營運而言,無論年對年或連續季度來看都非常亮眼。這是否是一個可維持、並可作為未來擴張業務的基礎?我想,折舊費用可能會更高。但撇開那點不談,我是說,這樣的獲利水準是否可持續,並且能從這裡再成長?我的問題是:是否有任何季節性因素,或是有補進度(catch up)在發生?
Timothy Tyson - President and COO
Timothy Tyson - President and COO
This is Tim Tyson, thank you for your compliments, we appreciate that. Yes, we believe the growth is sustainable and we do believe that we have a foundation from which to grow. We believe that the base business can grow similar to what the industry growth rates will be and INS data suggests somewhere in the 5-10% range and we expect to further that growth through further pipeline development.
我是 Tim Tyson,謝謝你的稱讚,我們很感謝。是的,我們認為成長是可持續的,也相信我們已建立可用來擴張的基礎。我們認為基礎業務的成長可與產業成長率相近,而 INS 的資料顯示大約在 5% 到 10% 的區間;我們也預期透過進一步的產品線(pipeline)開發來推動更高的成長。
Matt Tiplus - Analyst
Matt Tiplus - Analyst
Thank you.
謝謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
One of the things to supplement Tim's comments -- one of the things, of course to add to that will be the ability to evolve and bring to the market additional products. We have been somewhat constrained from that as we've been going through our restructuring phase, but one of the things we initiated and reported to you a year ago is that we have reorganized and re-emphasized life cycle management programs across the company and we now have a consolidated 20-plus projects in the pipeline, not 6 which we brought to the market since our beginning of that effort.
補充 Tim 的評論——當然,其中一項補充是我們能夠逐步演進並把更多產品帶到市場。由於我們正處於重整階段,這方面多少受到限制;但我們一年前啟動並向各位報告的一件事是:我們已在全公司重新組織並重新強調產品生命週期管理計畫,而現在我們在產品線中有整合後超過 20 個專案,而不是 6 個——那 6 個是我們自那項努力開始以來已推向市場的。
That will start to come to play as we move later into 2004 in the next six to 18 months and clearly have a full impact as we reach out into 2005. So that's something we've already done the lead work. The efforts are under way and we'll start to reap the benefits of that as we move later into 2004. In addition to whatever we do on the acquisition side.
這些將在 2004 年稍晚、未來 6 到 18 個月開始發揮作用,並且在我們進入 2005 年時明顯產生完整影響。所以這是我們已經完成前期鋪陳的事情。相關工作正在進行中,我們會在 2004 年稍晚開始收穫其效益。此外還包括我們在併購面所做的任何事情。
Operator
Operator
Your next question comes from a Larry Smith with DLS Research.
下一個問題來自 DLS Research 的 Larry Smith。
Larry Smith - Analyst
Larry Smith - Analyst
Yes. I was wondering if the guidance that you gave in September still holds for 2004, which was five to ten percent revenue growth of 34 to 36%, selling expense of 30 to 32% and G&A of 20 to 21 percent and also, could you give us some help on what R&D and amortization might be in 2004?
是的。我想請問你們 9 月給的 2004 年指引是否仍然成立:營收成長 5% 到 10%、毛利率 34% 到 36%、銷售費用 30% 到 32%、以及 G&A 20% 到 21%。另外,你們能否提供一些協助,說明 2004 年的研發費用與攤銷可能會是多少?
Timothy Tyson - President and COO
Timothy Tyson - President and COO
Let me take -- this is Tim Tyson. Yes, we're confident of that guidance. We're still performing so that we believe we will meet those results. And you can see some significant improvements towards those activities and towards the margins that we communicated. We have significant focus on each one of those areas, a lot of activity and you can see some progress towards the objectives. On the R&D expense and the amortization I'm going to ask Bary to comment.
我先回答——我是 Tim Tyson。是的,我們對該指引有信心。我們目前的表現讓我們相信會達成那些結果。而你也可以看到我們朝向那些活動以及我們所溝通的利潤率有一些顯著改善。我們對每一個領域都有高度聚焦,做了很多工作,你也能看到朝目標前進的一些進展。至於研發費用與攤銷,我會請 Bary 來評論。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
On the amortization expense, as we mentioned in my earlier comment, amortization should increase about 17.50 million in 2004 as a result of the amortization of the royalty, the intangible that was booked associated with the royalty. Depreciation again obviously non-cash charges, depreciation is up as I indicated before as a result of the fact we've accelerated depreciation on the that we anticipate divesting of so sure at the manufacturing operations. That should help us shouldn't be other factors affecting amortization.
關於攤銷費用,如同我先前的評論所提到的,由於對權利金進行攤銷(也就是與該權利金相關、已入帳的無形資產),2004 年攤銷費用應會增加約 1,750 萬。折舊同樣顯然是非現金費用;如我先前所指出,折舊上升是因為我們已加速對預期將處分的資產進行折舊,確實是在製造營運方面。這應該會對我們有所幫助,攤銷應不會有其他因素影響。
Larry Smith - Analyst
Larry Smith - Analyst
It looks like your numbers are substantially better than what you're indicating on your cost ratios. If looks like your COGS is going to come in at 31,5 next year and your guidance for next year is 34 to 36. Am I missing something? Is there a reason to think that 2004 will see an acceleration of cost of goods sold?
看起來你們的數字明顯比你們在成本比率上所指引的要好。看起來你們明年的銷貨成本(COGS)會落在 31.5 左右,而你們對明年的指引是 34% 到 36%。是我漏掉了什麼嗎?是否有理由認為 2004 年銷貨成本會加速上升?
Timothy Tyson - President and COO
Timothy Tyson - President and COO
There's a couple of issues there. We are doing exceptionally well and have had a good quarter. One quarter is only a point on a curve and so there's a number of things that we have to do. As we've communicated we're focused on achieving those five year targets and there is going to be some investment required to achieve a couple of those margins.
這裡有幾個議題。我們表現非常好,這一季也很不錯。但單一季度只是曲線上的一個點,因此我們還有很多事情要做。如同我們所溝通的,我們專注於達成五年目標,而要達成其中幾個利潤率目標將需要一些投資。
And so especially in cost of goods, you have to initiate a project which we have begun to rationalize our facilities and there's some expense in relocating the products and in reregistering them in other markets. So we are going to have to spend some money next year to do those things and we expect to see some accelerating benefit and majority of the benefit past 2005.
因此,特別是在銷貨成本方面,你必須啟動一個專案;我們已開始精簡我們的設施,而在搬遷產品以及在其他市場重新註冊方面會有一些費用。所以明年我們必須花一些錢來做這些事,我們預期會看到一些加速的效益,而大部分效益會在 2005 年之後顯現。
Larry Smith - Analyst
Larry Smith - Analyst
But I guess the one thing I'm trying to figure out is are you changing your guidance? You know, are you still saying 34 to 36% COGS ratio in 2004? Are you still saying 30 to 32% selling expenses?
但我想我試著弄清楚的一件事是:你們是否在改變指引?你知道,你們仍然是說 2004 年銷貨成本比率為 34% 到 36% 嗎?你們仍然是說銷售費用為 30% 到 32% 嗎?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Larry, the simple answer is we're changing nothing.
Larry,簡單的答案是:我們什麼都不改。
Larry Smith - Analyst
Larry Smith - Analyst
That's still remains your guidance?
那仍然是你們的指引?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Yes. What we've stated in the past is what we're sticking with. If in fact some of these developments mature into what results as a trend, we'll re-evaluate of course, but remember, 2004 is a period of some relatively heavy investment for us in the transformation particularly in the manufacturing rationalization plan, a the lot of those investments haven't started to kick in. So again, come back to Tim's point, one quarter doesn't a trend make, but clearly we're pleased a lot of the right things are happening.
是的。我們過去所說的就是我們會堅持的。如果這些發展確實成熟並形成趨勢性的結果,我們當然會重新評估;但請記得,2004 年對我們而言是相對重投資的期間,特別是在製造精簡計畫的轉型上,而許多投資尚未開始發揮效益。所以再次呼應 Tim 的觀點:一個季度不構成趨勢;但很明顯,我們很高興很多正確的事情正在發生。
Larry Smith - Analyst
Larry Smith - Analyst
If I follow your guidance I come in with about a 60 to 65 cents a share next year. Is that the message you want to leave us with?
如果我依照你們的指引來算,明年每股大約是 0.60 到 0.65 美元。這是你們希望留給我們的訊息嗎?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
You will have to draw your own conclusions, Larry?
Larry,你得自己下結論。
Larry Smith - Analyst
Larry Smith - Analyst
OK.
好的。
Operator
Operator
Again to ask a question, please press "*" and then the number '1' on your telephone keypad. Your next question comes from a Michael Stanski with Tudor investments. That question has been withdrawn. Your next question comes from Derek Winker with Jeffries and company.
再次提醒,如要提問,請在電話鍵盤按下「*」再按數字「1」。下一個問題來自 Tudor Investments 的 Michael Stanski。該問題已撤回。下一個問題來自 Jefferies and Company 的 Derek Winker。
Derek Winker - Analyst
Derek Winker - Analyst
Yes, thank you I have many financial questions. Can I give them to you all at once or do you want them one by one?
是的,謝謝。我有很多財務問題。我可以一次把它們都提出來,還是你們希望我一個一個問?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
We would like to try to limit it to one question because we have other people that have questions, too. So if you can give us, if you will your most important ones, we'll try to respond to those and come back as time permits.
我們希望盡量限制為一個問題,因為也有其他人要提問。所以如果你能提出你最重要的問題,我們會嘗試回應,若時間允許再回來處理其他問題。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
And We'll certainly stay on line to let you come back into the queue.
我們也一定會留在線上,讓你可以再回到提問隊列。
Derek Winker - Analyst
Derek Winker - Analyst
The gross interest expense for the quarter D&A and CAPEX, I had others.
本季的利息費用總額、折舊與攤銷(D&A)以及資本支出(CAPEX),我還有其他的。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
I'm sorry? What's the question?
不好意思?你的問題是什麼?
Timothy Tyson - President and COO
Timothy Tyson - President and COO
Gross interest?
利息總額?
Derek Winker - Analyst
Derek Winker - Analyst
Expense.
費用。
Timothy Tyson - President and COO
Timothy Tyson - President and COO
Yes and CAPEX.
是的,還有 CAPEX。
Derek Winker - Analyst
Derek Winker - Analyst
And D&A.
以及 D&A。
Timothy Tyson - President and COO
Timothy Tyson - President and COO
OK.
好的。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
We'll get back to you in just a minute on the interest expense and what was the other?
我們稍後馬上回覆你利息費用;另一個是什麼?
Derek Winker - Analyst
Derek Winker - Analyst
CAPEX and D&A.
CAPEX 和 D&A。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
CAPEX for the year historically our trends have been around $20 million a year. We're expecting our CAPEX for the year to be a little over 50% of what that historical trend has been in continuing operations. We don't expect that to continue into 2004. We expect to go back to normal CAPEX our historical CAPEX run rates in 2004.
就年度 CAPEX 而言,歷史趨勢大約每年 2,000 萬美元。我們預期今年持續營運的 CAPEX 會略高於該歷史趨勢的 50%。我們不預期這種情況會延續到 2004 年。我們預期 2004 年會回到正常的 CAPEX,也就是我們歷史的 CAPEX 執行水準。
Derek Winker - Analyst
Derek Winker - Analyst
What is it year-to-date or in the third quarter?
那年初至今是多少,或第三季是多少?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
The year-to-date is 9 million. Gross interest expense is $7.9 million.
年初至今是 900 萬。利息費用總額是 790 萬美元。
Timothy Tyson - President and COO
Timothy Tyson - President and COO
OK. What was the other question?
好的。另一個問題是什麼?
Derek Winker - Analyst
Derek Winker - Analyst
What was the depreciation and amortization in the quarter? I believe that's in the table. Yes in the financial. Hold on a second.
本季的折舊與攤銷是多少?我相信那在表格裡。是的,在財務資料裡。等我一下。
Timothy Tyson - President and COO
Timothy Tyson - President and COO
16.8 million for the quarter and 45.8 year-to-date.
本季是 1,680 萬,年初至今是 4,580 萬。
Derek Winker - Analyst
Derek Winker - Analyst
45.8 year-to-date?
年初至今 4,580 萬?
Timothy Tyson - President and COO
Timothy Tyson - President and COO
That's correct.
沒錯。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
OK. Derek.
好的。Derek。
Derek Winker - Analyst
Derek Winker - Analyst
Thank you.
謝謝。
Operator
Operator
Your next question comes from a Michael Stanski (ph) with Tudor Investment.
下一個問題來自 Tudor Investment 的 Michael Stanski(音)。
Michael Stanski - Analyst
Michael Stanski - Analyst
Could you comment on the impact of capital utilization from lowering the plant level in '04 and '05? And Bary what would be the tax rate we should use for '04?
你們能否評論一下,透過在 04 與 05 年降低工廠層級所帶來的資本使用率影響?另外,Bary,我們在 04 年應該使用的稅率是多少?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Michael, thanks for your call. The capacity utilization at the conclusion of the plant will more than double and it will progress over the next few years, so I don't expect significant improvements next year as next year will mostly be re-registration activities an movement of equipment and capabilities. So most benefit will come after those happen. But we'll more than double at the conclusion.
Michael,謝謝你的來電。在工廠結束時的產能利用率將會增加到兩倍以上,並且會在未來幾年逐步提升;因此我不預期明年會有顯著改善,因為明年主要會是重新註冊活動以及設備與能力的移轉。所以大部分效益會在那些完成之後才會出現。但在結束時我們會增加到兩倍以上。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
And rose to the tax rate, Michael, as we communicated at the Bear Stearns conference, and we're sticking to these projections, if you will, next year tax rates will be between 36 and 37%.
至於稅率,Michael,如同我們在 Bear Stearns 會議上所溝通的,而且我們會維持這些預估,明年的稅率將介於 36% 到 37%。
Michael Stanski - Analyst
Michael Stanski - Analyst
OK. Do you expect any meaningful cash flow from selling those plants or they'll just be closed down?
好的。你們預期出售那些工廠會帶來任何有意義的現金流嗎?還是它們只會被關閉?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
The manufacturing facilities?
製造設施嗎?
Michael Stanski - Analyst
Michael Stanski - Analyst
Yes.
是的。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
No, we're not expecting anything substantial.
不,我們不預期會有任何可觀的金額。
Michael Stanski - Analyst
Michael Stanski - Analyst
Thank you.
謝謝。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Thank you.
謝謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
However, Michael, they will be sold. That is our first priority, but don't expect to realize a great deal.
不過,Michael,它們會被出售。那是我們的第一優先,但不要預期能實現很大的金額。
Michael Stanski - Analyst
Michael Stanski - Analyst
That's a significant point.
那是一個重要的點。
Operator
Operator
Your next question comes from a John Buzz Bosalari (ph) with GIC capital.
下一個問題來自 GIC Capital 的 John Buzz Bosalari(音)。
John Bosalari - Analyst
John Bosalari - Analyst
Thank you. Good morning. Can you go over the inventory, if you will? How much was taken last year and where we stand now?
謝謝。早安。可以請你們說明一下存貨嗎?去年提列了多少,目前我們的狀況如何?
Timothy Tyson - President and COO
Timothy Tyson - President and COO
I can tell you where we stand now. We're back to normal industry rates, which are in the one to two months of supply and have been since April and we continue to basically have inventories that reflect real demand. So we're back at normal rates and have been since April and Bary is going to comment on last year.
我可以告訴你我們目前的狀況。我們已回到正常的產業水準,也就是供應量約一到兩個月,自四月以來一直如此,而且我們基本上持續維持反映實際需求的庫存水位。所以我們自四月以來就回到正常水準,而Bary會評論去年的情況。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Yes, as we mentioned last year, associated with the third quarter, the impact of whole sale inventory reduction program was approximately $10 million for the third quarter.
是的,如同我們去年提到的,與第三季相關的批發庫存削減計畫之影響,第三季約為1,000萬美元。
John Bosalari - Analyst
John Bosalari - Analyst
Last year?
去年?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Last year.
去年。
John Bosalari - Analyst
John Bosalari - Analyst
OK. Thank you.
好的。謝謝。
Operator
Operator
Your next question comes from a Brian Turner with Seligman.
下一個問題來自Seligman的Brian Turner。
Brian Turner - Analyst
Brian Turner - Analyst
Thank you for taking my call. Congratulations on a great third quarter. The way I would model this on veer ram dean going out, could I assume I probably start to see sales in '06 and then accelerating in '07? One of the things that I, part of the feedback I've gotten from many docks is the cost of pro-krit because of the anemia is so expensive that a lot of docs would love to see this come in earlier than later, if that were the case, could you see coming in earlier in '06? Or where do you stand on that?
謝謝接聽我的電話。恭喜第三季表現非常出色。我在建模ver ram dean未來走勢時,是否可以假設我大概會在06年開始看到銷售,並在07年加速?我從許多醫師那裡得到的部分回饋是,因為貧血而使用pro-krit的成本非常昂貴,所以很多醫師希望這個產品能越早上市越好;如果是這樣的話,你們是否可能在06年更早導入?或者你們目前的立場是什麼?
Timothy Tyson - President and COO
Timothy Tyson - President and COO
As Robert indicated, we aren't communicating any significant details about ver ram dean, but we have said and continue to expect that product to come to the market in 2007. And of course, we have competent people here and we're looking at everything possible to accelerate that, but right now, our position remains in the 2007 area. This is a life threatening disease. You know, this is a benefit, we know there is a significant cost out there to anemia treatment, so we are concerned for patients and we're doing everything possible to accelerate those dates.
如Robert所指出,我們不會對ver ram dean溝通任何重大細節,但我們已表示且仍預期該產品將於2007年上市。當然,我們這裡有能力很強的人才,也在檢視一切可能加速的方式,但目前我們的立場仍是在2007年左右。這是一種危及生命的疾病。你知道,這是一項效益;我們也知道貧血治療在外部有顯著成本,因此我們關心病患,並盡一切可能加速這些時程。
Brian Turner - Analyst
Brian Turner - Analyst
Al right. Thanks, guys. Great quarter.
好的。謝謝各位。第三季很棒。
Operator
Operator
Your next question come from Suzanne Henigan with Rorer Asset Management.
下一個問題來自Rorer Asset Management的Suzanne Henigan。
Suzanne Henigan - Analyst
Suzanne Henigan - Analyst
Hello. Could you just tell us what the growth in you're mean sales would have been ex-currency?
你好。你能否告訴我們,若排除匯率因素,你們的mean銷售成長會是多少?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Yes, we have in table 6 to our earnings release, we outlined the impact of foreign currency.
可以,我們在盈餘新聞稿的表6中列出了外幣的影響。
Suzanne Henigan - Analyst
Suzanne Henigan - Analyst
OK.
好的。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
In European sales if you, the impact on European sales was $4.8 million as compared to the same period last year.
就歐洲銷售而言,與去年同期相比,對歐洲銷售的影響為480萬美元。
Suzanne Henigan - Analyst
Suzanne Henigan - Analyst
Got it thanks.
了解,謝謝。
Operator
Operator
I have a follow-up question from Michael Tong from Wachovia securities.
我有一個來自Wachovia Securities的Michael Tong的追問。
Michael Tong - Analyst
Michael Tong - Analyst
Thanks for taking the follow-up. I just want to clarify, excluding the accelerated depreciation and the cost of moving products and projects around the globe, would you expect gross margin on product sales to be at this level going forward? Again, excluding all that depreciation. And secondly, if I can sneak one more in, any idea how much, what percent of Vir amidine is converted into Ribavirin in the body?
謝謝讓我追問。我只是想確認一下,若排除加速折舊,以及將產品與專案在全球各地移轉的成本,你們是否預期未來產品銷售的毛利率會維持在這個水準?再說一次,排除所有那些折舊。第二,如果我可以再問一個,你們知道Vir amidine在體內有多少比例會轉換成Ribavirin嗎?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
The question on the gross margin and the cost of goods is a complex one, as you know. What I can tell is that the cost of goods is going down because of two major things that we're doing. Number one, focusing on North America, generating different sales profiles so as we increase our sales in a higher margin market, it's improving our gross margin.
關於毛利率與銷貨成本的問題,如你所知相當複雜。我能告訴你的是,銷貨成本正在下降,主要因為我們正在做兩件事。第一,聚焦北美,形成不同的銷售組合;當我們在高毛利市場的銷售增加時,毛利率就會改善。
As we're focusing on manufacturing, we're improving efficiencies, increasing productivity and focusing on taking out unnecessary cost and waste, we will be decreasing the cost of goods by that focus. So without those other things, yes, we are confident we will see a continuing trends or report reduction of our cost of goods towards that 20 to 25% cost of goods target.
當我們聚焦製造端時,我們正在提升效率、提高生產力,並著重去除不必要的成本與浪費;透過這些努力,我們將降低銷貨成本。因此,若不考慮那些其他因素,是的,我們有信心會看到持續的趨勢,或是我們的銷貨成本將朝20%到25%的銷貨成本目標下降。
It will take some time because we still have all of these facilities and we are doing the things necessary to improve our productivity as rapidly as possible. And regarding conversion of Vir amidine to Ribavirin, we don't know that yet in human trials. We will in the course of the clinical development do the kinds of study that will give us that answer. In animal studies, it is well north of 70% as converted.
這需要一些時間,因為我們仍有所有這些設施,而我們正採取必要措施,盡可能快速提升生產力。至於Vir amidine轉換成Ribavirin的比例,我們在人體試驗中目前還不知道。在臨床開發過程中,我們會進行能提供答案的研究。在動物研究中,轉換比例遠高於70%。
Michael Tong - Analyst
Michael Tong - Analyst
Great. Thank you.
很好。謝謝。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Thank you.
謝謝。
Operator
Operator
We have a follow-up from Matt Tiplus with Quaker Capital Management.
我們有一個來自Quaker Capital Management的Matt Tiplus的追問。
Matt Tiplus - Analyst
Matt Tiplus - Analyst
Just wanted to clarify a couple remarks as relates to next year's broad earnings guidance. The amortization expense, I'm just trying to remember, was that caught out as a separate item or is that included in those percentages given? And in the other question as you discussed I guess you are characterizing significant investments next year for re qualification, plant moving, that sort of thing. Is it your anticipation that most of that is expensed as opposed to capitalized?
我想釐清幾點,關於你們對明年整體盈餘指引的說法。攤銷費用,我只是想回想一下,那是被單獨剔除列示,還是已包含在你們給出的那些百分比之中?另外一個問題是,你們提到明年會有重大投資用於重新認證、工廠搬遷之類的事情。你們是否預期其中大部分會認列為費用,而不是資本化?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Relative to amortization expense it was not carved out separately. Again, you would expect to see our historical amounts for this year and add to it or historical trend add to it the increase that we suggested. Recognizing that for 2003 some of that impact will be reflected in the annualized 2003 result. Relative to the cost of moving the product, In all, you would not expect to capitalize any of those costs. Those would be expensed.
關於攤銷費用,並沒有單獨剔除。同樣地,你會預期看到我們今年的歷史金額,並在此基礎上加上我們所提到的增幅,或依歷史趨勢加上該增幅。並注意到2003年其中部分影響會反映在2003年全年年化結果中。至於產品移轉的成本,整體而言,你不會預期我們會將任何這些成本資本化。這些都會費用化。
Matt Tiplus - Analyst
Matt Tiplus - Analyst
OK. Just so I'm straight then, when the numbers, I'm just taking notes from the other questioner, but the 30, 32% of sales, you know, in selling that 34 to 36 cost of goods and I can't remember what the G&A guidance was.
好的。那我確認一下,當你們提到那些數字時——我只是從前一位提問者那邊做筆記——銷售費用占銷售額30%到32%,銷貨成本34%到36%,我不記得G&A的指引是多少。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
21.
21。
Matt Tiplus - Analyst
Matt Tiplus - Analyst
None of those include the amortization, is that correct?
這些都不包含攤銷,對嗎?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
That is correct.
正確。
Matt Tiplus - Analyst
Matt Tiplus - Analyst
So it would be on top of those?
所以攤銷會是在這些之上另外加上去?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Yes.
是的。
Matt Tiplus - Analyst
Matt Tiplus - Analyst
OK. Thank you.
好的。謝謝。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Thank you.
謝謝。
Operator
Operator
We have a follow-up from Alan Seymour with Columbia management.
我們有一個來自Columbia Management的Alan Seymour的追問。
Alan Seymour - Analyst
Alan Seymour - Analyst
Yes. I'd like a little more detail, if you might, on how you kind of allocate your R&D dollars in terms of maybe either killing projects or giving me some sense of how you prioritize things? Obviously that's going to be important as you go forward?
是的。如果可以的話,我想更詳細了解你們如何分配研發經費,例如是否會終止專案,或讓我了解你們如何設定優先順序?顯然,這在你們往前走時會很重要。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Well, we are just beginning to put together what I would call portfolio management. And it is a series of ten or 20 different risk factors and timing et cetera that we work very closely with the commercial group to do. And based on the output of those is the way we would allocate dollars to R&D.
嗯,我們才剛開始建立我所稱的投資組合管理(portfolio management)。這是一套包含十到二十個不同風險因子、時程等的流程,我們會與商業團隊非常密切地合作來進行。而我們會依據這些輸出結果來分配研發經費。
Alan Seymour - Analyst
Alan Seymour - Analyst
All right. Thanks.
好的。謝謝。
Operator
Operator
We have a follow-up question from Larry Smith with DLS research.
我們有一個來自DLS Research的Larry Smith的追問。
Larry Smith - Analyst
Larry Smith - Analyst
I just wanted to see if we could pin you down a little bit more on R&D. It looks like with Vir amidine is in phase three trial that your core R&D when Vir amidine was in phase two, your core R&D seemed to be running at about, $10 million per quarter. As you go into a broad phase three trial with a thousand patients on Vir amidine vis-a-vis at 150 or so in the phase two trial, shouldn't we expect a very significant ramp-up in R&D in 2004? Perhaps as much as taking it from, something like 41 million this year to 57 million? Am I missing anything? Is that a fairly good way of looking at it?
我只是想看看能不能讓你們在研發方面再講得更具體一些。看起來Vir amidine已進入第三期試驗;當Vir amidine在第二期時,你們的核心研發費用似乎約為每季1,000萬美元。當你們進入一項涵蓋1,000名病患的Vir amidine大型第三期試驗(相較於第二期約150名左右),我們是否應該預期2004年的研發費用會大幅攀升?甚至可能從今年約4,100萬提高到5,700萬?我是不是漏掉了什麼?這樣看是否相當合理?
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
Let me just characterize back to what we said. We did consider this as you could expect in our discussion at the Bear Stearns conference and our 10 to 12% of sales is still in the range that we think is going to be needed. That is an increase over what we've been spending and that considers the phase three trials that we're doing. And the phase three trials, as you know, will take more than one year, at least there will be some activity in a couple of years.
讓我回到我們先前所說的內容來做個說明。正如你所預期的,我們在 Bear Stearns 會議上的討論中確實已考量到這點,而我們將研發支出維持在銷售額的 10% 到 12% 之間,仍在我們認為所需的範圍內。這比我們過去的支出水準有所增加,並且已納入我們正在進行的第三期試驗。而第三期試驗,如你所知,將會超過一年,至少在接下來幾年都會有一些相關活動。
Robert O'Leary; I would like to reinforce that. Just remember, that these are long studies that we said earlier that patient participation alone is 72 weeks. So certainly the R&D expense would be spread over probably three or more fiscal years.
Robert O'Leary;我想再強調一下。請記得,這些都是長期研究;我們先前提過,僅病患參與期就有 72 週。因此,研發費用很可能會分攤在三個或更多個會計年度。
Larry Smith - Analyst
Larry Smith - Analyst
OK. Thank you.
好的。謝謝。
Timothy Tyson - President and COO
Timothy Tyson - President and COO
I guess in summary, we expect the R&D expense to go up. I'm not sure we would use the word significant as you did in your question. But we expect it to go up consistent with what we have committed to in the 10 to 12% total range of sales after we committed to it at the Bear Stearns conference. Nothing about these developments in the last 24 hours has in any way changed our perspective on that and we believe the numbers we have given you previously are solid for the inclusion of phase three trials.
我想總結來說,我們預期研發費用會上升。我不確定是否會用你在問題中所用的「顯著」一詞。但我們預期它會上升,並與我們在 Bear Stearns 會議上承諾的、占總銷售額 10% 到 12% 的區間一致。過去 24 小時內的這些發展,並未以任何方式改變我們對此的看法;我們相信先前提供給各位的數字是穩健的,並已包含第三期試驗。
Operator
Operator
Your next question comes from a Robert Uhl with Wells Fargo.
下一個問題來自 Wells Fargo 的 Robert Uhl。
Robert Uhl - Analyst
Robert Uhl - Analyst
Thank you. I just had a question about the royalty stream and the percent of that that might be starting to arise from KOPIGAS if any of it is? And what does that do to the international portion that is safe from generic competition? And then one other thing on the share count is the lower number that we saw in Q3 what the base will be going forward? Thank you.
謝謝。我有個關於權利金收入流的問題:其中有多少比例可能開始來自 KOPIGAS(如果有的話)?這對於國際市場中可免於學名藥競爭的那一部分有何影響?另外還有一點,關於股數:我們在第三季看到的較低數字,是否會成為未來的基準?謝謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Go ahead on the share.
先談股數吧。
Bary Bailey - EVP and CFO
Bary Bailey - EVP and CFO
On the share count, yes, that's the base. It reflects the fact that earlier in our divestiture activity we brought back in a little over a million shares on one of the sales. So that should be your base count for shares going forward.
關於股數,是的,那就是基準。這反映了我們先前在資產剝離活動中,於其中一筆出售交易回購了略多於一百萬股。因此,這應該就是你未來所採用的基本流通股數。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
On the royalty, we don't break out the difference between the rates or the amounts from Roche or Shering. We do know that our royalties this quarter were significantly impacted by Shering's earnings release comments and activities. And the 60% of the non U.S. that I mentioned is a stable and growing -- contains both Roche and shering royalties.
至於權利金,我們不會拆分來自 Roche 或 Schering 的費率或金額差異。我們確實知道,本季權利金受到 Schering 財報發布中的評論與相關活動的顯著影響。我提到的非美國地區 60% 的部分,是穩定且成長中的——其中同時包含 Roche 與 Schering 的權利金。
Operator
Operator
Your next comes from a Vick Roy with Bain capital.
下一個問題來自 Bain Capital 的 Vick Roy。
Vick Roy - Analyst
Vick Roy - Analyst
Hello. Thanks for taking my question and congratulations on the great results. I'm curious to know if you decided on which regulated Interferon you'll use in the phase three trial or will you use both given that both are widely used now and obviously would be good to see Vir amidine data with both Interferons? Thanks very much.
你好。謝謝讓我提問,也恭喜你們有很棒的成果。我想了解,你們是否已決定在第三期試驗中會使用哪一種已核准的干擾素?還是會兩種都用,因為目前兩者都被廣泛使用,而且顯然也很有價值看到 Vir amidine 搭配兩種干擾素的數據?非常感謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
We have not yet decided which one we're going do in the current trial, the trial we're about to start.
我們尚未決定在目前這個、即將啟動的試驗中要使用哪一種。
Vick Roy - Analyst
Vick Roy - Analyst
And what thought process will you use to make that decision, do you think?
那你們會用什麼樣的思考流程來做這個決定呢?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Well, we obviously at the end of the day would like to have information with both regulated Interferons, it's just a matter of strategically in what order we do those trials?
嗯,很明顯,最終我們希望能取得兩種已核准干擾素的資訊;只是策略上要以什麼順序來做這些試驗的問題。
Vick Roy - Analyst
Vick Roy - Analyst
Great. Got it. Thanks very much.
很好。了解了。非常感謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Thank you.
謝謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Operator, as we're running up to the close of the hour, if we could take perhaps two more questions.
接線員,由於時間快到整點結束了,我們或許可以再接兩個問題。
Operator
Operator
Your next question is a follow-up question from Derek Winger with Jeffries and company.
下一個問題是來自 Jefferies and Company 的 Derek Winger 的追問。
Derek Winker - Analyst
Derek Winker - Analyst
Yes. Thank you. Do you have own balance sheet items there?
是的。謝謝。你們那邊有自己的資產負債表項目嗎?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
We have in the press release on the attached exhibits you should have additional balance sheet items reflected on table five.
在新聞稿的附表展覽中,你應該可以在表五看到更多資產負債表項目。
Derek Winker - Analyst
Derek Winker - Analyst
Is current assets, current liabilities, current portion, long-term debt and intangibles on there?
裡面有流動資產、流動負債、流動部分、長期負債以及無形資產嗎?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
What you have in there is cash, accounts receivable inventory, and long-term debt. We have not communicated the others yet.
你在那裡看到的是現金、應收帳款、存貨,以及長期負債。其他項目我們尚未對外揭露。
Derek Winker - Analyst
Derek Winker - Analyst
OK. When do you expect filing the Q?
好的。你們預計何時提交 Q(季報)?
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Obviously it's got too come up in the next week.
很明顯,必須在接下來一週內完成。
Derek Winker - Analyst
Derek Winker - Analyst
OK. Thank you.
好的。謝謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
You're welcome.
不客氣。
Operator
Operator
Our last question is a follow-up question from Unidentified with RT capital.
我們最後一個問題是來自 RT Capital 的一位未具名人士的追問。
Unidentified
Unidentified
Robert, you answered my question. Thanks a lot.
Robert,你已經回答了我的問題。非常感謝。
Robert O'Leary - Chairman and CEO
Robert O'Leary - Chairman and CEO
Thank you, John. I want to thank everyone today. This is obviously an exciting time for the management. We're completely pumped up about the quarter, of course and excited about extraordinary results out of our R&D capability and under Dr. Laman's leadership. I want to thank you all for joining us today. We're as pleased at about our performance and prospects for the future. You can expect to hear more news from us in the near future as we break away from the past and accelerate our plans for building shareholder value. Thank you and good morning.
謝謝你,John。我也要感謝今天在場的各位。這對管理團隊而言顯然是個令人振奮的時刻。我們對本季表現當然非常振奮,也對我們研發能力所帶來的卓越成果、以及在 Laman 博士領導下的表現感到興奮。感謝各位今天加入我們。我們對自身的表現以及未來前景同樣感到滿意。隨著我們擺脫過去並加速推動提升股東價值的計畫,各位可望在不久的將來聽到我們更多消息。謝謝,早安。
Operator
Operator
This concludes today's ICN third quarter conference call. Thank you for your participation. At this time, you may now disconnect from the conference.
以上為今日 ICN 第三季電話法說會的全部內容。感謝各位的參與。此刻您可以結束連線並離開會議。